文献速递眼底病与葡萄膜炎

BNT162b2 mRNA 2019冠状病毒病疫苗接种与非感染性葡萄膜炎之间的关联:一项基于人群的研究

Association between Vaccination with the BNT162b2 mRNA Coronavirus Disease 2019 Vaccine and Noninfectious Uveitis: A Population-Based Study.
PubMed 文献 · Ophthalmology · 2022-05-25

该回顾性人群研究纳入2 602 557名2020年12月20日至2021年4月30日接种第一剂BNT162b2 mRNA新冠疫苗者及2 441 719名2021年1月10日至4月30日接种第二剂者,评估接种后21天内活动性非感染性葡萄膜炎事件。以2019年人群经验为参照,第一剂后年龄和性别调整SIR为1.41(95%CI 1.15-1.71),第二剂后为1.31(95%CI 1.05-1.62)。作者认为疫苗可能与活动性非感染性葡萄膜炎风险升高相关,但效应量小且研究存在局限,不提供因果关系证据。

要点

  • 第一剂后21天内记录100例活动性非感染性葡萄膜炎事件,年龄和性别调整SIR为1.41(95%CI 1.15-1.71)。
  • 第二剂后21天内记录88例事件,年龄和性别调整SIR为1.31(95%CI 1.05-1.62)。
  • 前葡萄膜炎最常见(占90.96%的眼),特发性葡萄膜炎最常见病因(56.38%)。

核心结论

  • 本研究提示BNT162b2 mRNA新冠疫苗可能与活动性非感染性葡萄膜炎风险升高相关,但考虑效应量小及研究局限性,不提供因果关系证据。
  • 估计的归因风险较小,提示对公共卫生的影响相对轻微。

研究设计与样本

  • 回顾性、基于人群的研究。
  • 纳入2 602 557名于2020年12月20日至2021年4月30日接种第一剂疫苗者,及2 441 719名于2021年1月10日至2021年4月30日接种第二剂疫苗者。
  • 活动性非感染性葡萄膜炎事件定义为需开始或增加局部或全身糖皮质激素治疗的新发活动性或加重性眼部炎症,纳入接种任一次剂量后21天内发生的事件。
  • 观察病例数与基于2019年人群经验的预期数比较。

主要发现

  • 第一剂后21天内记录100例活动性非感染性葡萄膜炎事件,年龄和性别调整SIR为1.41(95%CI 1.15-1.71),21天归因风险为每10万名接种者1.12例。
  • 第二剂后21天内记录88例事件,SIR为1.31(95%CI 1.05-1.62),估计归因风险为每10万名接种者0.86例。
  • 前葡萄膜炎是最常见的炎症部位,占90.96%的眼;特发性葡萄膜炎是最常见病因,占56.38%。

局限性

  • 原文指出研究存在局限性,但摘要未逐条列出具体局限内容。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To assess the association between BNT162b2 mRNA coronavirus disease 2019 (COVID-19) vaccine and the risk of active noninfectious uveitis (NIU). DESIGN: Retrospective, population-based study. PARTICIPANTS: Two million six hundred two thousand five hundred fifty-seven people who received the first vaccine dose between December 20, 2020, and April 30, 2021, and 2 441 719 people who received the second vaccine dose between January 10, 2021, and April 30, 2021. METHODS: Events of active NIU were included if they occurred within 21 days after either vaccine dose. Active NIU was defined as newly active or worsening ocular inflammation requiring initiation or increase in local or systemic corticosteroids. Observed cases were compared with the expected number, based on the experience of the population in 2019. MAIN OUTCOME MEASURES: Age- and sex-adjusted standardized incidence ratios (SIRs) and attributable risks after BNT126b2 vaccination. RESULTS: Overall, 100 and 88 events of active NIU were recorded within 21 days after the first and second vaccine doses, respectively. Using the experience of the population in 2019 as a reference, after the first dose, the estimated age- and sex-adjusted SIR was 1.41 (95% confidence interval [CI], 1.15-1.71) along with a 21-day attributable risk of 1.12 cases per 100 000 vaccinees. After the second dose, the SIR was 1.31 (95% CI, 1.05-1.62), with an estimated attributable risk of 0.86 cases per 100 000 vaccinees. Anterior uveitis was the most common site of inflammation, occurring in 90.96% of eyes, and idiopathic uveitis was the most common cause (56.38%). CONCLUSIONS: This study suggests that the BNT162b2 mRNA COVID-19 vaccine may be associated with an increased risk of active NIU. However, considering the small effect size and study limitations, this study does not provide proof for a cause-and-effect relationship. The small estimated attributable risks suggest that the impact on public health is relatively minor.

来源:Ophthalmology,查看原文。版权归原作者所有。

引用

  1. Tomkins-Netzer O, Sar S, Barnett-Griness O, et al. Association between Vaccination with the BNT162b2 mRNA Coronavirus Disease 2019 Vaccine and Noninfectious Uveitis: A Population-Based Study. Ophthalmology. 2022. PMID: 35643168. doi:10.1016/j.ophtha.2022.05.015

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。